Defining the Incidence and Associated Morbidity and Mortality of Severe Respiratory Syncytial Virus Infection Among Children with Chronic Diseases

Manzoni, Paolo; J, Figueras Aloy; Simões, Eric A F; Checchia, Paul A.; Fauroux, Brigitte; Bont, Louis; Paes, Bosco; Carbonell‐Estrany, Xavier

doi:10.1007/s40121-017-0160-3

Cited by 69 publications

(79 citation statements)

References 72 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Infrequent deaths in industrialized countries associate with complex comorbidities ranging from chronic lung and heart disease to transplants. 17,19 In developing country hospitals, suboptimal medical care during emergencies and secondary bacterial infections can lead to poor outcomes. 13,16,25,27 And hazardous environmental exposures and social handicaps may team up to weaken the lung and/or delay medical care, converting a routine viral infection at home into a lethal ailment.…”

Section: Resultsmentioning

confidence: 99%

“…Other children suffering chronic diseases that can experience severe RSV infections are transplant patients . While RSV‐attributable CFR are typically <10% in immunocompromised children, these numbers are higher in transplant patients.…”

Section: Mortality Due To Rsv In Industrialized Countriesmentioning

confidence: 99%

“…18 Other children suffering chronic diseases that can experience severe RSV infections are transplant patients. 19…”

Section: Mortality Due To Rsv In Industrialized Countriesmentioning

confidence: 99%

See 2 more Smart Citations

Respiratory syncytial virus is an “opportunistic” killer

Caballero

Polack

2018

Pediatric Pulmonology

View full text Add to dashboard Cite

Respiratory syncytial virus (RSV), responsible for more than three million yearly hospitalizations and up to 118 000 deaths in children under 5 years, is the leading pulmonary cause of death for this age group that lacks a licensed vaccine. Ninety‐nine percent of deaths due to the virus occur in developing countries. In‐hospital RSV fatalities affect previously healthy term infants in association with bacterial sepsis, clinically significant pneumothoraxes and, to a lesser extent, comorbid conditions. Community deaths affect low‐income children from socially vulnerable families and appear to be as frequent as inpatient fatalities. In industrialized countries, RSV deaths occur almost exclusively in children with premorbid conditions.In a sense, RSV is an “opportunistic” killer. It needs a synergistic premorbid, medical practice‐related, infectious, or social co‐factor to cause a fatal outcome. But while the complex problems associated with these co‐factors await solutions, candidate vaccines, long‐lived monoclonal antibodies and antivirals against RSV are under clinical evaluation. It seems reasonable to predict that the landscape of RSV infections will look different in the next decade.

show abstract

Section: Resultsmentioning

confidence: 99%

Section: Mortality Due To Rsv In Industrialized Countriesmentioning

confidence: 99%

See 1 more Smart Citation

Respiratory syncytial virus is an “opportunistic” killer

Caballero

Polack

2018

Pediatric Pulmonology

View full text Add to dashboard Cite

show abstract

“…Infection by RSV has variable symptoms from a mild and self‐limiting upper respiratory tract infection to severe bronchiolitis and pneumonia with hyperinflated lungs and hypoxemia . Severe RSV infection in infants is often associated with prematurity, birth defects, chronic lung disease, congenital heart defects, and immunodeficiency . Nevertheless, the majority of infants hospitalized for RSV infection are previously healthy and do not fit the profile of a high‐risk patient .…”

Section: Introductionmentioning

confidence: 99%

Disease severity in respiratory syncytial virus infection: Role of host genetic variation

Tahamtan

Askari

Bont

et al. 2019

Reviews in Medical Virology

Self Cite

View full text Add to dashboard Cite

Summary Respiratory syncytial virus (RSV) infection is the most common cause of bronchiolitis and pneumonia in the pediatric population worldwide. The immunopathology of RSV infection varies considerably and severe disease occurs only in a minority of the population. There are many factors (host, viral, and environmental) that contribute to the complicated disease phenotype. In this regard, host factors are decisive for pulmonary susceptibility to RSV infection. Host genetic diversity certainly affects the balance between control of viral replication and tissue damage during RSV infection, consequently impacting on diseases outcome. In this review, we discuss the role of host genetic variation in disease caused by RSV aiming to highlight genetic risk factors for one of the most common diseases in early childhood. Our findings clearly indicate that the response of each individual to infection is influenced by genetic diversity mainly linked to the regulation of host immune responses. Future genetic association and functional studies using more powerful and consistently reproducible approaches will likely be able to confirm, refine, and expand our developing concept of RSV disease pathogenesis.

show abstract

“…A recent metaanalysis indicates that in infants with Down syndrome, irrespectively of prematurity and congenital heart disease, there is an effect in reducing hospitalizations due to RSV [7].…”

mentioning

confidence: 99%

Untitled

2017

Klin Padiatr

View full text Add to dashboard Cite

EditorialRecent data indicate that the number of children cared for respiratory syncytial virus (RSV) infections in hospitals is in the range of 50,000 to 100,000 per year in the United States [3]. Major risk factors include apart from prematurity specifically below 29 weeks, congenital heart defects, Down syndrome and further congenital anomalies. The American Academy of Pediatrics recommended in 2014 a restriction of Palivizumab prophylaxis to preterm infants of < 29 weeks of gestation and those with a high-risk course postnatally and higher gestational ages apart from specific indications resulting from congenital anomalies including congenital heart defects [1].In the current issue of the Klinische Pädiatrie, a group from Bosnia-Herzegovina published data on the effects of prophylactic immunization with Palivizumab on the occurrence of RSV infection in preterm neonates and other high-risk children [6].Main data of the present study indicate that out of 101 children about 49 % were preterm neonates, 40 % had a congenital heart defect and 11 % exhibit individual risk factors. The authors showed clearly that out of 101 children, who were treated prophylactically with Paliviziumab, none was hospitalized due to RSV infection. Despite the small number of the enrolled infants and older children, the data indicate that also under conditions of a reduced economical state of the National Health Service, the prophylaxis is working adequately.However, there still remain some questions open with respect to efficacy of Palivizumab. 1. The number of preterm neonates being enrolled in the trial was relatively low, thus, giving only a restricted measurement of effectiveness of Palivizumab. 2. The data have to be interpreted with caution, since the effects of Palivizumab have been restricted to somewhat less than 50 % of preterm neonates, the further treated children of the group are either affected by congenital heart disease or by other disorders, e. g. neurologic problems, cardiopulmonary anomalies among others.In a recently published multicenter analysis enrolling pediatric hospitals from the Northern as well as from the Southern hemisphere (United States, Canada, Italy, The Netherlands and Australia), infants were enrolled, if they were born prematurely ( < 36 weeks of gestation) and were younger than 24 months. In the second year of life, only infants with the diagnosis of bronchopulmonary dysplasia (BPD) or related pulmonary disorders were enrolled [3]. Out of more than 1,000 preterm neonates enrolled in this study, about 900 were able to be identified as the group with adequate data available. Main results of this study include that Palivizumab was used in about 430 infants, whereas it was not given in 415 neonates serving as controls. RSV was identified in 47 % on occasion of either outpatient or hospitalized care in enrolled children with respiratory symptoms. RSV was identified in a total of 403 neonates, the effect of Palivizumab for intensive care admission was a risk reduction 58 % (CI 43-69 % on the 95 % level)...

show abstract

Defining the Incidence and Associated Morbidity and Mortality of Severe Respiratory Syncytial Virus Infection Among Children with Chronic Diseases

Cited by 69 publications

References 72 publications

Respiratory syncytial virus is an “opportunistic” killer

Respiratory syncytial virus is an “opportunistic” killer

Disease severity in respiratory syncytial virus infection: Role of host genetic variation

Untitled

Contact Info

Product

Resources

About